Table I.

Main features of the 3 patients reported with moderate to severe immune induced/aggravated psoriasis

Sex/age	Cancer/anti-PD-1	Psoriasis type	Latency period	Past psoriatic treatment	Apremilast treatment period	Body sites affected	Initial psoriasis severity	Final psoriasis severity	Malignancy progression/ time to progression with apremilast	Estimated progression free survival mean time of anti-PD1 treatment/reference	Apremilast adverse effects
Male/50 years	Stage IV Uveal melanoma/nivolumab	New onset plaque psoriasis with psoriatic arthritis	5 months	–∗	12 months	Trunk, soles, upper and lower extremities Asymmetric oligoarthritic involvement	PASI 12 BSA 15 % PGA 3	PASI 3.40 BSA 8% PGA 1	None/–∗	2.8 months12	Auto limited diarrhea
Male/70 years	Stage IV laryngeal carcinoma/nivolumab	Exacerbated Plaque psoriasis with intertriginous psoriasis	2 weeks	Acitretin 25 mg/day	10 months	Trunk, upper and lower extremities, axillar and sub-mammary folds	PASI 13.80 BSA 15% PGA 3	PASI 3 BSA 4% PGA 1	Yes/10 months	2 months13	Mild headache
Male/60 years	Stage IV squamous lung cell carcinoma/nivolumab	Exacerbated plaque psoriasis with intertriginous psoriasis	1 week	Mometasone furoate ointment	10 months	Lower extremities, inguinal and genital folds	PASI 6.40 BSA 4% PGA 3	PASI 4 BSA 3% PGA 1	Yes/10 months	3.5 months14	None

BSA, Body surface area; PASI, psoriasis area severity index; PD1, programmed cell death protein 1; PGA, physician's global assessment.

^∗– = not applicable.